



EXPRESS MAIL NO.: EV 475 143 202 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kunz Confirmation No.: 1690
Application No.: 09/910,388 Art Unit: 1656
Filed: July 20, 2001 Examiner: Robinson, Hope A.
For: THERAPEUTIC INHIBITOR OF Attorney Docket No.: 10177-211-999
VASCULAR SMOOTH MUSCLE (formerly 295.003US5)
CELLS

TERMINAL DISCLAIMER FEE TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The fee for processing the attached Terminal Disclaimer is believed to be **\$130.00**. Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Date: September 18, 2006

Gidon D. Stern 27,469
Gidon D. Stern (Reg. No.)

By: Ann W. Chen 49,013
Ann W. Chen (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosure



EXPRESS MAIL NO.: EV 475 143 202 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Kunz	Confirmation No.:	1690
Application No.:	09/910,388	Art Unit:	1656
Filed:	July 20, 2001	Examiner:	Robinson, Hope A.
For:	THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS	Attorney Docket No.:	10177-211-999 (formerly 295.003US5)

TERMINAL DISCLAIMER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Scimed Life Systems, Inc., now known as Boston Scientific Scimed, Inc. ("Scimed"), *see* Exhibit 1, is the assignee of the entire right, title and interest in and to the above-identified application by virtue of an assignment which was recorded on April 18, 2003 at reel 013974, frame 0188.

Scimed is also the assignee of the entire right, title and interest in and to U.S. Patent Nos. 5,981,568; 6,663,881; 5,733,925; 6,074,659; and 6,268,390 by virtue of the same assignment which was recorded on April 18, 2003 at reel 013974, frame 0188.

The undersigned, on behalf of Scimed, hereby disclaims the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of any of U.S. Patent Nos. 5,981,568; 6,663,881; 5,733,925; 6,074,659; and 6,268,390, as such term is defined in 35 U.S.C. §§ 154 and 173, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent Nos. 5,981,568; 6,663,881; 5,733,925; 6,074,659; and 6,268,390.

The undersigned further agrees that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns and that any patent granted on that application or any patent subject to the

NYJD-1627300v2

09/21/2006 RHEBRAHT 00000040 503013 09910388

01 FC:1814 130.00 DA

reexamination proceeding shall be enforceable only for and during such period that said patent is commonly owned with the application or patent which formed the basis for the rejection.

The undersigned does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any of U.S. Patent Nos. 5,981,568; 6,663,881; 5,733,925; 6,074,659; and 6,268,390 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R.

§ 1.321(a), has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

The undersigned hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is authorized to act on behalf of Scimed.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 18 day of SEPTEMBER, 2006

Scimed Life Systems, Inc.
(now known as Boston Scientific Scimed, Inc.)

By:

Name: Scott T. Bluni, Esq.
Position/Title: Assistant Secretary